Founded in 2010 and headquartered in Cleveland, Ohio, Enspire DBS Therapy is building a first-in-class neuromodulation solution that pairs deep brain stimulation (DBS) with structured rehabilitation to restore upper-extremity function after stroke. Its lead program is being evaluated in the multicenter RESTORE pivotal clinical trial, which implants a commercially available third-party DBS system and compares DBS + Rehab to rehabilitation alone in patients with chronic arm impairment. The study is being conducted under an FDA Investigational Device Exemption and is targeting long-term safety and effectiveness data needed for future U.S. marketing authorization, with interim results expected in mid-2027. Proceeds from recent funding will accelerate patient enrollment and trial execution. Financially, the company remains pre-commercial and recently secured $10.3 million in fresh capital, bringing additional institutional support and board expertise. Existing backers Cleveland Clinic and JobsOhio Ventures have recommitted to the venture alongside new lead investor Genesys Capital. Enspire aims to translate breakthrough neuroscience into clinically meaningful outcomes for the roughly 800,000 Americans who suffer a stroke each year.

Total raised

$10M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2026